Considering that melanoma cells with de novo MITF deficiency were consistently insensitive to DUSP4 depletion regardless of MAPKi sensitivity status, assessment of MITF levels in treatment-naive melanoma tumors would likely be necessary to stratify patients who are most likely to respond to DUSP4-targeted therapies. This evidence concerns the gene MITF and melanoma.